TLC-ART principal investigator and program director; professor and presidential entrepreneurial fellow at the University of Washington. |
Clinical Lead for the TLC-ART Program. |
Research Scientist in Dr. Ho’s lab since June 2021. PhD from UW in 2016; postdoctoral research in Materials Science and Engineering. |
Sr. Research Associate Scientist in physiologically-based mathematical and computational modeling (PBPK). Develops PK models of drug-combo nanoparticles for long-acting therapies in HIV, HBV, cancer, and SARS-CoV-2. |
PhD in Organic Chemistry, Brigham Young University (1990). Joined the lab in 2021. 27 years in drug discovery, contributing to two investigational drugs. |
Luqi Duan, Ph.D. PhD in Toxicology, University of Kansas Medical Center (2020). Expertise in toxicology, pharmacology, immunology, and molecular cell biology. Joined the lab in 2023. |
Keegan Klein, B.S. Research Scientist I in Dr. Ho’s lab since March 2024. Joined after industry experience as an aseptic technician at BioLife Solutions. |
Project Administrator for TLC-ART. Joined the lab in July 2019 after a postdoc in Political Science at the University of Notre Dame. |
Assistant Clinical Trial Manager for the TLC-ART program, reporting to Dr. Kristina Adams Waldorf. |
Data Scientist and Research Associate Professor of Psychiatry and Behavioral Sciences, reporting to Dr. Kristina Adams Waldorf. |